Keyword: Samsung BioLogics

CanSino reports positive data for COVID-19 vaccine. Takeda's Alunbrig wins first-line lung cancer nod. GSK inks $231 million deal with Samsung.

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

A lack of patients stopped two remdesivir trials in China. FDA cleared Lupin, Dr. Reddy’s and Biocon sites. CanSino's COVID-19 vax moves into phase 2.

Vir struck a manufacturing deal with Samsung to boost production of two novel antibodies that could prove effective as a treatment for COVID-19.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.

AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung execs.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

Biocon, whose problems at its plant in Bengaluru caused approval delays for a key drug, says the FDA has issued the plant an EIR.

WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.

Hansoh and Hengrui chiefs together make one of biopharma's richest families; prosecutors grill top Samsung exec; FDA cites another Aurobindo plant.